Comparison · NCT02155647-deaths
Part A: Avelumab vs Part B: Avelumab: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part A: Avelumab vs Part B: Avelumab: deaths from any cause. Trial comparisons, record NCT02155647-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02155647-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.716 | 0.614 | 0.8 | wilson | |
| Risk in group 2 | 0.621 | 0.53 | 0.704 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0952 | -0.0361 | 0.219 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.95 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 1.54 | 0.849 | 2.8 | log | |
| Number needed to harm, for one more death from any cause on Part A: Avelumab than on Part B: Avelumab | 10.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part A: Avelumab | Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs. | 63 | 88 | EG000 |
| Group 2 | Part B: Avelumab | Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs. | 72 | 116 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Part A: Up to 325 weeks; Part B: Up to 396 weeks
Source ClinicalTrials.gov
Trial
- Title
- Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
- NCT number
- NCT02155647
- Phases
- PHASE2
- Conditions
- Carcinoma, Merkel Cell
- Interventions
- Avelumab
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Results first posted
- 2020-07-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02155647?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02155647-deaths